|
業務類別
|
Biotechnology |
|
業務概覽
|
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005,a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases. |
| 公司地址
| 280 East Grand Avenue, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 231-6625 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.alumis.com |
| 員工數量
| 224 |
| Mr. Martin Babler |
Chairman of the Board, President and Chief Executive Officer |
美元 605.90K |
16/06/2025 |
| Mr. Derrick Richardson |
Senior Vice President, People and Culture |
-- |
16/06/2025 |
| Mr. Mark Bradley |
Chief Development Officer |
-- |
16/06/2025 |
| Dr. Jorn Drappa, M.D.,PhD |
Chief Medical Officer |
-- |
16/06/2025 |
| Mr. John R. Schroer |
Chief Financial Officer and Principal Accounting Officer |
-- |
16/06/2025 |
| Dr. David M. Goldstein, PhD |
Chief Scientific Officer |
美元 466.50K |
16/06/2025 |
| Mr. Roy C. Hardiman |
Chief Business and Strategy Officer |
美元 444.30K |
16/06/2025 |
| Ms. Sara Klein |
Chief Legal Officer and Corporate Secretary |
-- |
16/06/2025 |
|
|
| Mr. Martin Babler |
Chairman of the Board, President and Chief Executive Officer |
16/06/2025 |
| Ms. Lynn A. Tetrault, J.D. |
Independent Director |
21/05/2025 |
| Dr. James B. Tananbaum,M.D. |
Independent Director |
16/06/2025 |
| Mr. Patrick C. Machado, J.D. |
Independent Director |
16/06/2025 |
| Dr. Sapna Srivastava, PhD |
Independent Director |
16/06/2025 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Independent Director |
16/06/2025 |
| Dr. Alan B. Colowick, M.D.,M.P.H. |
Independent Director |
16/06/2025 |
| Dr. Zhengbin Yao, PhD |
Independent Director |
16/06/2025 |
|
|
|
|
